ATMP Process Development & Bioproduction Maturation

Advanced therapy medicinal products (ATMPs), including cell and gene therapies, often face critical bottlenecks when transitioning from early-stage development to robust, scalable and GMP-compliant manufacturing.

As part of the Établissement Français du Sang (EFS), we combine deep expertise in immune cell biology, access to biological resources, and integrated bioproduction capabilities.

Through our biotherapy innovation hub, we act as a single entry point to support ATMP maturation, with a strong focus on de-risking development and preparing efficient transfer to clinical manufacturing.

Our support includes:
• Process development and optimisation (robustness, reproducibility, scalability)
• Scale-up strategy and manufacturing readiness
• Quality control and analytical development
• Regulatory and CMC support

We work with biotech startups, pharma and academic teams to accelerate the transition from proof-of-concept to clinical stages.